Comparison of Two New Silicone Hydrogel Multifocal Products
Study Details
Study Description
Brief Summary
The purpose of this trial is to compare the performance of two multifocal contact lenses.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Lotrafilcon B / Senofilcon A Lotrafilcon B, followed by Senofilcon A |
Device: Lotrafilcon B multifocal contact lens
Silicone hydrogel, soft, multifocal contact lens for daily wear use
Device: Senofilcon A multifocal contact lens
Silicone hydrogel, soft, multifocal contact lens for daily wear use
|
Other: Senofilcon A / Lotrafilcon B Senofilcon A, followed by Lotrafilcon B |
Device: Lotrafilcon B multifocal contact lens
Silicone hydrogel, soft, multifocal contact lens for daily wear use
Device: Senofilcon A multifocal contact lens
Silicone hydrogel, soft, multifocal contact lens for daily wear use
|
Outcome Measures
Primary Outcome Measures
- Corrected Distance Binocular Visual Measurement in Normal Illumination Reported as Binocular Distance Visual Acuity [After 1 week of wear]
Tested while reading charts distant to the subject with both eyes together in normal lighting. This outcome is measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 equates to 20/20 Snellen acuity and is considered normal. Positive logMAR values indicate poorer vision and negative values denote better visual acuity.
- Corrected Near Binocular Visual Measurement in Normal Illumination Reported as Binocular Near Visual Acuity [After 1 week of wear]
Tested while reading charts at 40 cm with both eyes together in normal lighting. This outcome is measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 equates to 20/20 Snellen acuity and is considered normal. Positive logMAR values indicate poorer vision and negative values denote better visual acuity.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
At least 35 years of age
-
Best-corrected visual acuity of at least 20/40 in each eye.
-
Spectacle add between +0.75D and +1.50D (inclusive).
-
Able to be fit in available study sphere powers (-0.50 to -5.50D).
-
Currently wearing soft contact lenses at least 5 days a week.
-
Other protocol inclusion/exclusion criteria may apply.
Exclusion Criteria:
-
Requires concurrent ocular medication.
-
Eye injury or surgery within twelve weeks immediately prior to enrollment.
-
Currently enrolled in an ophthalmic Clinical Trial.
-
Evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions.
-
Previous refractive surgery.
-
Astigmatism > 1.00D.
-
Currently wearing ACUVUE OASYS for PRESBYOPIA.
-
Other protocol inclusion/exclusion criteria may apply.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- CIBA VISION
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- P-319-C-005 sub 7
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail | Two participants were enrolled but not dispensed due to failing inclusion criteria. These participants were included in the Actual Enrollment calculation, but not Participant Flow or Baseline Characteristics calculations. |
Arm/Group Title | Lotrafilcon B / Senofilcon A | Senofilcon A / Lotrafilcon B |
---|---|---|
Arm/Group Description | Lotrafilcon B multifocal contact lens worn first, followed by Senofilcon A multifocal contact lens worn second. Both products were worn on a daily-wear basis. | Senofilcon A multifocal contact lens worn first, followed by Lotrafilcon B multifocal contact lens worn second. Both products were worn on a daily-wear basis. |
Period Title: Period 1 | ||
STARTED | 19 | 19 |
COMPLETED | 19 | 19 |
NOT COMPLETED | 0 | 0 |
Period Title: Period 1 | ||
STARTED | 19 | 19 |
COMPLETED | 16 | 17 |
NOT COMPLETED | 3 | 2 |
Baseline Characteristics
Arm/Group Title | Overall |
---|---|
Arm/Group Description | This reporting group includes all enrolled and dispensed subjects |
Overall Participants | 38 |
Age (years) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [years] |
47.6
(4.7)
|
Sex: Female, Male (Count of Participants) | |
Female |
30
78.9%
|
Male |
8
21.1%
|
Outcome Measures
Title | Corrected Distance Binocular Visual Measurement in Normal Illumination Reported as Binocular Distance Visual Acuity |
---|---|
Description | Tested while reading charts distant to the subject with both eyes together in normal lighting. This outcome is measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 equates to 20/20 Snellen acuity and is considered normal. Positive logMAR values indicate poorer vision and negative values denote better visual acuity. |
Time Frame | After 1 week of wear |
Outcome Measure Data
Analysis Population Description |
---|
Per protocol. Analysis excluded major protocol deviations as determined by masked review. |
Arm/Group Title | Lotrafilcon B Multifocal Contact Lens | Senofilcon A Multifocal Contact Lens |
---|---|---|
Arm/Group Description | Silicone hydrogel, soft, multifocal contact lens | Silicone hydrogel, soft, multifocal contact lens |
Measure Participants | 33 | 33 |
Mean (Standard Deviation) [LogMAR] |
-0.08
(0.04)
|
-0.04
(0.06)
|
Title | Corrected Near Binocular Visual Measurement in Normal Illumination Reported as Binocular Near Visual Acuity |
---|---|
Description | Tested while reading charts at 40 cm with both eyes together in normal lighting. This outcome is measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 equates to 20/20 Snellen acuity and is considered normal. Positive logMAR values indicate poorer vision and negative values denote better visual acuity. |
Time Frame | After 1 week of wear |
Outcome Measure Data
Analysis Population Description |
---|
Per protocol. Analysis excluded major protocol deviations as determined by masked review. |
Arm/Group Title | Lotrafilcon B Multifocal Contact Lens | Senofilcon A Multifocal Contact Lens |
---|---|---|
Arm/Group Description | Silicone hydrogel, soft, multifocal contact lens | Silicone hydrogel, soft, multifocal contact lens |
Measure Participants | 33 | 33 |
Mean (Standard Deviation) [LogMAR] |
0.05
(0.11)
|
0.10
(0.14)
|
Adverse Events
Time Frame | 9 weeks, duration of the study | |||
---|---|---|---|---|
Adverse Event Reporting Description | 1 week of wear for each intervention | |||
Arm/Group Title | Lotrafilcon B Multifocal Contact Lens | Senofilcon A Multifocal Contact Lens | ||
Arm/Group Description | Silicone hydrogel, soft, multifocal contact lens | Silicone hydrogel, soft, multifocal contact lens | ||
All Cause Mortality |
||||
Lotrafilcon B Multifocal Contact Lens | Senofilcon A Multifocal Contact Lens | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
Lotrafilcon B Multifocal Contact Lens | Senofilcon A Multifocal Contact Lens | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/39 (0%) | 0/38 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
Lotrafilcon B Multifocal Contact Lens | Senofilcon A Multifocal Contact Lens | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/39 (0%) | 0/38 (0%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any pre-clinical and/or clinical data or impressions from this trial.
Results Point of Contact
Name/Title | Priya Janakiraman, OD, FAAO / Head, Global Clinical Affairs |
---|---|
Organization | CIBA VISION |
Phone | 1-800-241-7629 |
priya.janakiraman@cibavision.com |
- P-319-C-005 sub 7